New antimicrobial agents for use in the intensive care unit

Area of Science:

• Infectious Diseases
• Critical Care Medicine
• Pharmacology

Background:

• Antimicrobial resistance is a growing threat in intensive care units (ICUs), complicating the treatment of bacterial and fungal infections.
• Multidrug regimens are often necessary to cover common ICU pathogens, but resistance limits treatment options.
• The Infectious Diseases Society of America (IDSA) highlights the impact of antimicrobial-resistant pathogens on patient care.

Purpose of the Study:

• To review emerging antibacterial and antifungal agents for treating infections in the ICU setting.
• To address the challenge of antimicrobial resistance posed by ESKAPE pathogens.

Main Methods:

• Review of select antibacterial agents in late-stage clinical development.
• Review of an antifungal agent in late-stage clinical development.
• Focus on agents with potential for treating infections caused by common ICU pathogens.

Main Results:

• Identification of promising antimicrobial agents in late-stage development.
• Highlighting agents with potential to overcome resistance mechanisms of ESKAPE pathogens.
• Discussion of agents suitable for the ICU environment.

Conclusions:

• New antimicrobial agents are crucial for managing infections in ICUs.
• Emerging therapies show potential in combating resistant pathogens like ESKAPE organisms.
• Continued development of novel antimicrobials is essential to address the evolving landscape of infectious diseases.